10-Q: Elevance Health Q3 Revenue Soars, But 9-Month Profit Dips

Elevance Health reported strong third-quarter revenue and EPS growth, yet nine-month net income and operating cash flow declined amidst rising medical costs and a significant litigation settlement.

Summary

• Operating revenue for the three months ended September 30, 2025, increased by 12.0% to $50,087 million, driven by premium rate increases, recent acquisitions, and Medicare Advantage growth.
• Diluted earnings per share (EPS) for the third quarter rose by 22.0% to $5.32.
• For the nine months ended September 30, 2025, operating revenue increased by 13.9% to $148,273 million.
• However, net income for the nine months decreased by 8.0% to $5,115 million, and diluted EPS fell by 4.8% to $22.67.
• Operating cash flow for the nine months decreased to $4,206 million from $5,102 million in the prior year, primarily due to a $666 million Provider Settlement Agreement payment and lower net income.
• Medical membership declined by 0.9% year-over-year to 45.4 million, mainly due to decreases in the BlueCard business and Medicaid attrition from eligibility redeterminations, partially offset by Medicare Advantage growth.
• The benefit expense ratio increased for both the three and nine months, reflecting higher medical cost trends in Medicare (due to Part D seasonality related to the IRA) and Commercial ACA plans.
• The operating expense ratio decreased for both periods, indicating improved operating leverage.
• Elevance Health issued $3,000 million in new senior unsecured notes and repaid $2,150 million in existing notes, and increased its common stock repurchase program authorization by $8,000 million in October 2024, with $7,166 million remaining.

Sentiment

Score: 6

Explanation: The Q3 performance was strong with significant revenue and EPS growth, and improved operating efficiency. However, the nine-month results show a decline in net income and operating cash flow, primarily due to elevated medical cost trends and a large litigation settlement. Membership attrition in key segments and ongoing regulatory uncertainties present notable headwinds. The improved Medicare Star Ratings and strategic acquisitions are positive, but the overall picture is mixed with significant challenges to navigate.

Positives

• Third-quarter 2025 operating revenue increased by 12.0% to $50,087 million.
• Third-quarter 2025 diluted EPS increased by 22.0% to $5.32.
• Operating expense ratio decreased by 130 basis points in Q3 and 120 basis points for the nine months, demonstrating improved operating leverage.
• Medicare Advantage membership grew by 9.7% year-over-year, adding 198,000 members.
• CarelonRx operating revenue increased by 20.3% in Q3 and 22.2% for the nine months, with nine-month operating gain up 3.4%.
• Carelon Services operating revenue increased by 57.9% in Q3 and 61.5% for the nine months, with operating gain up 19.0% in Q3 and 62.8% for the nine months, driven by acquisitions and expansion of risk-based capabilities.
• Effective tax rate decreased significantly in Q3 (15.6% vs. 26.6%) and for the nine months (21.2% vs. 23.8%) due to investment credits and the non-recurrence of a prior year uncertain tax position.
• Debt-to-capital ratio improved to 42.1% at September 30, 2025, from 43.0% at December 31, 2024.
• The 5-Year Facility credit agreement was amended and restated, extending its maturity to September 2030 and increasing available credit from $4,000 million to $5,000 million.
• 2026 Medicare Advantage Star Ratings reflect 55% of members in plans rated at least 4.0 Stars or higher, an improvement from 40% for 2025 Star Ratings.

Negatives

• Nine-month 2025 net income decreased by 8.0% to $5,115 million compared to the prior year.
• Nine-month 2025 diluted EPS decreased by 4.8% to $22.67.
• Operating cash flow for the nine months decreased by $896 million, primarily due to the $666 million Provider Settlement Agreement payment and lower net income.
• Total medical membership declined by 0.9% year-over-year, driven by decreases in the BlueCard business and Medicaid attrition due to eligibility redeterminations.
• Benefit expense ratio increased by 180 basis points in Q3 and 170 basis points for the nine months, indicating higher medical cost trends, particularly in Medicare and Commercial ACA plans.
• Health Benefits segment operating gain decreased significantly by 62.5% in Q3 and 27.5% for the nine months, attributed to higher medical cost trends and increased investments.
• CarelonRx operating gain decreased by 10.2% in Q3 due to expenses associated with the expansion of dispensing services.
• Medicaid cost trends remain elevated due to higher population acuity and increased utilization of services.
• Net losses on financial instruments increased for the nine months ended September 30, 2025, compared to the prior year.

Risks

• Medical cost trends are subject to variance from estimates due to changes in utilization, unit costs, regulatory changes, aging population, health status, epidemics, pandemics, advances in medical technology, new high-cost prescription drugs, provider contracting inflation, labor costs, and healthcare fraud, waste, and abuse.
• Membership shifts from Medicaid into Individual ACA business following redetermination, coupled with lower effectuation rates, have driven a market-wide increase in morbidity and elevated medical cost trends.
• Pricing of Medicare and Medicaid programs may not adequately reflect current underlying healthcare cost trends due to timing lags, potentially adversely affecting financial results.
• The One Big Beautiful Bill Act (OBBBA) contains various provisions, including changes to Medicaid rules, work requirements, cost sharing, and home equity thresholds, with most effective dates in 2027 and 2028, which could impact business and operations.
• The Marketplace Integrity and Affordability Regulation modifies ACA exchange open enrollment and eligibility for premium tax credits, with some provisions delayed by a federal court pending litigation.
• New mental health parity regulations require administrative and operational changes, with the full impact uncertain pending additional guidance from the Tri-Agencies.
• The expiration of enhanced Premium Tax Credits (PTC) at the end of 2025, if not extended by Congress, could have a material adverse effect on business and results of operations.
• CMS plans to substantially increase the scale and pace of Risk Adjustment Data Validation (RADV) audits of Medicare Advantage plans, which could increase financial recoveries from plans and adversely affect financial condition.
• Ongoing Blue Cross Blue Shield Antitrust Litigation, including follow-on cases from opt-out entities, could result in unanticipated outcomes and material adverse effects.
• The U.S. Department of Justice's civil lawsuit regarding Medicare Risk Adjustment Litigation alleges false certification of diagnosis data and failure to delete inaccurate codes, potentially leading to significant liabilities.
• Involvement in other pending and threatened litigation, governmental investigations, audits, and reviews could result in civil or criminal fines, penalties, or restrictions on business operations.
• Claims arising from decisions to restrict or deny reimbursement for uncovered services could lead to significant punitive damage awards.
• A downgrade in credit ratings could adversely impact business, liquidity, financial condition, and results of operations by limiting future borrowings and increasing borrowing costs.
• Failure to effectively maintain and modernize information systems, or failure of information systems or technology (including artificial intelligence) to operate as intended, poses a risk.
• Changes in economic and market conditions, as well as regulations, may negatively affect liquidity and investment portfolios.
• Possible impairment of the value of goodwill and other intangible assets if future results do not adequately support their carrying value.
• Possible restrictions in the payment of dividends from subsidiaries and increases in required minimum levels of capital.

Future Outlook

Elevance Health anticipates that the Public Exchange will be influenced by policy and regulatory changes, particularly concerning federal subsidies, compliance, and market stability. The company is implementing program improvements, strengthening care management, and optimizing its clinical strategy to mitigate elevated Medicaid cost trends. Further regulatory guidance on Medicare, including ratings and quality bonus payments, is expected. CMS plans to significantly increase Risk Adjustment Data Validation (RADV) audits for Medicare Advantage plans. The potential expiration of enhanced Premium Tax Credits (PTC) at the end of 2025 could materially impact the business. The company expects to utilize its remaining common stock repurchase authorization over a multi-year period and believes its current liquidity and future cash flows will be sufficient for operations, commitments, and strategic transactions.

Management Comments

• We are working on program improvements in partnership with the states, strengthening care management, and optimizing our clinical strategy to improve effectiveness and lower costs.

Industry Context

The health insurance industry is navigating a complex environment characterized by elevated medical cost trends, particularly in Medicaid and Individual ACA markets, partly due to ongoing Medicaid eligibility redeterminations. Regulatory changes, such as the One Big Beautiful Bill Act (OBBBA) and CMS's Marketplace Integrity and Affordability Regulation, are introducing new compliance requirements and policy shifts that will impact operations and financial models. The industry is also seeing a continued focus on value-based care and integrated health services, as evidenced by Elevance Health's acquisitions in these areas and the growth of its CarelonRx and Carelon Services segments. The emphasis on Medicare Advantage Star Ratings underscores the competitive landscape and the importance of quality performance for bonus payments.

Comparison to Industry Standards

• Elevance Health's 2026 Medicare Advantage Star Ratings show that approximately 55% of its members are enrolled in plans rated at least 4.0 Stars or higher, an improvement from 40% for the 2025 payment year. This indicates a positive trend in quality performance relative to its own prior year, a key industry benchmark for Medicare Advantage plans.

Corporate Governance

Legal Proceedings

• Blue Cross Blue Shield Antitrust Litigation: Multiple lawsuits alleging horizontal allocation of geographic markets. The Provider Settlement Agreement received final approval in August 2025, with a $666 million monetary payment made on September 19, 2025. Several follow-on cases from opt-out entities (e.g., Alaska Air, JetBlue, Bed Bath & Beyond, Hoover, VHS Liquidating Trust) are ongoing.
• Medicare Risk Adjustment Litigation: U.S. Department of Justice civil lawsuit alleging false certification of diagnosis data and failure to delete inaccurate codes, leading to unspecified amounts of Medicare overpayments. Fact discovery is ongoing with a December 9, 2025 deadline, and expert discovery until June 18, 2026. A temporary Order of Stay was issued on October 1, 2025, for civil cases by the U.S. Attorney's Office for the Southern District of New York.
• Other Contingencies: Involvement in other pending and threatened litigation and governmental investigations, audits, reviews, and administrative proceedings. Claims for coverage decisions (restricting or denying reimbursement) could result in significant punitive damage awards.

Related Party Transactions

• Mosaic Health provided care delivery and enablement services to Elevance Health subsidiaries amounting to $162 million for the three months and $662 million for the nine months ended September 30, 2025, reported in benefit expense.
• Liberty Dental provided services to Medicare Advantage members under a capitated arrangement amounting to $149 million for the three months and $441 million for the nine months ended September 30, 2025, reported in benefit expense.

Stakeholder Impact

• Shareholders: Impacted by mixed financial results (strong Q3, weaker 9-month profit), dividend declarations ($1.71/share for Q4 2025), and the ongoing common stock repurchase program, which reduces share count.
• Members: Affected by medical cost trends, premium rate changes, and regulatory shifts (e.g., Medicaid redeterminations, ACA provisions). Improved Medicare Star Ratings for 2026 indicate potential for enhanced quality of care for Medicare Advantage members.
• Providers: Impacted by the Provider Settlement Agreement, which includes expansion of contracting opportunities, prompt pay commitments, and technological enhancements to the BlueCard program.
• Employees: The 2023-2024 Business Efficiency Program, finalized in December 2024, involved staff reductions and job function relocations, with associated cash outlays continuing through 2025.
• Regulators: Engaged with the company through various government actions, inquiries, and audits, particularly concerning antitrust, Medicare risk adjustment, and new healthcare legislation.

Next Steps

• Continue to vigorously defend follow-on cases in the Blue Cross Blue Shield Antitrust Litigation.
• Continue to vigorously defend the Medicare Risk Adjustment Litigation, with fact discovery ongoing until December 9, 2025, and expert discovery until June 18, 2026.
• Implement non-monetary terms of the Provider Settlement Agreement, including expanding provider contracting opportunities, prompt pay commitments, and technological enhancements to the BlueCard program.
• Work on program improvements, strengthening care management, and optimizing clinical strategy to improve effectiveness and lower Medicaid costs.
• Assess the full impact of mental health parity regulations pending additional guidance from the Tri-Agencies.
• Monitor the completion of Medicaid eligibility redeterminations by states, with a deadline of December 31, 2025.
• Evaluate the effects of ASU 2025-05 (Financial Instruments—Credit Losses), ASU 2024-03 (Income Statement—Expense Disaggregation Disclosures), and ASU 2025-06 (Intangibles—Goodwill and Other—Internal-Use Software) on consolidated financial statements and disclosures.
• Utilize the remaining authorized amount of the common stock repurchase program over a multi-year period, subject to market and industry conditions.
• Pay a fourth quarter 2025 dividend of $1.71 per share on December 19, 2025, to shareholders of record on December 5, 2025.

Key Dates

Recommendation

While Elevance Health demonstrated strong Q3 2025 revenue and EPS growth, the nine-month results reflect a decline in net income and operating cash flow, primarily due to elevated medical cost trends and a substantial litigation settlement. The company is actively addressing these challenges through strategic acquisitions in value-based care and pharmacy services, efficiency programs, and robust capital management, including an expanded credit facility and ongoing share repurchases. Improved Medicare Star Ratings are a positive indicator of quality. However, ongoing regulatory uncertainties, membership attrition in certain segments, and significant litigation (Blue Cross Blue Shield Antitrust and Medicare Risk Adjustment) pose material headwinds. The mixed financial performance and external pressures suggest a 'Hold' recommendation, as investors should await clearer evidence of sustained profitability improvement and resolution of key risks before making a more definitive investment decision.

Keywords

Health Insurance, Managed Care, Medicare Advantage, Medicaid, Pharmacy Services, CarelonRx, Carelon Services, SEC Filing, 10-Q, Financial Results, Medical Costs, Regulatory Risk, Antitrust Litigation, Risk Adjustment, Capital Management, Elevance Health